United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 32 mg

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride injection is indicated for the relief of moderate to severe pain such as that due to: surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. hydromorphone hydrochloride injection is contraindicated in patients with a known hypersensitivity to hydromorphone, in the presence of an intracranial lesion associated with increased intracranial pressure and whenever ventilatory function is depressed (chronic obstructive pulmonary disease, cor pulmonale, emphysema, kyphoscoliosis, status asthmaticus). [see warnings . ] narcotic analgesics, including hydromorphone, are contraindicated in premature infants or during labor when delivery of a premature infant is anticipated. hydromorphone hydrochloride injection is a schedule ii controlled narcotic substance. hydromorphone is known to be subject to abuse. opiates produce relaxation, indifference to pain and stress, lethargy and euphoria. patients who receive narcotics regularly for more than a few days may exhibit mild symptoms, which may not be recognized as withdrawal, upon discontinuation of therapy. however, the overwhelming majority of patients who receive opiates for medical reasons do not develop drug-seeking behavior or compulsive drug use. personality characteristics play a major role in determining which patients are likely to abuse drugs. hydromorphone must be administered only under close supervision to patients with a history of drug abuse or dependence. psychological dependence, physical dependence and tolerance are known to occur with hydromorphone. therefore, hydromorphone should be prescribed and administered with caution. the severity of the abstinence syndrome is related to the degree of dependence, the abruptness of withdrawal and the drug used. if the abstinence syndrome is precipitated by administration of a narcotic antagonist, symptoms appear within a few minutes and are maximal within thirty minutes. administration of a narcotic antagonist as a means of detecting dependence is not usually recommended. withdrawal symptoms in patients dependent on hydromorphone include yawning; sweating; lacrimation; rhinorrhea; a restless, tossing sleep; dilated pupils; goose flesh; irritability; tremor; nausea; vomiting and diarrhea. treatment of the abstinence syndrome is primarily symptomatic and supportive, including maintenance of proper fluid and electrolyte balance. tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is manifested initially by a shortened duration of analgesic effect and subsequently by decreases in the intensity of analgesia. the rate of development of tolerance varies among patients.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 2 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 2 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

ethypharm - hydromorphone hydrochloride - solution for injection/infusion - 20 milligram(s)/millilitre - natural opium alkaloids; hydromorphone

Ireland - English - HPRA (Health Products Regulatory Authority)

ethypharm - hydromorphone hydrochloride - solution for injection/infusion - 50 milligram(s)/millilitre - natural opium alkaloids; hydromorphone

United States - English - NLM (National Library of Medicine)

stat rx usa llc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 8 mg - exalgo is an extended-release oral formulation of hydromorphone hydrochloride indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. patients considered opioid tolerant are those who are taking at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day or an equianalgesic dose of another opioid, for a week or longer. exalgo is not intended for use as an as-needed analgesic. exalgo is not indicated for the management of acute or postoperative pain. exalgo is contraindicated in opioid non-tolerant patients. fatal respiratory depression could occur in patients who are not opioid tolerant. exalgo is contraindicated in patients with significant respiratory depression, especially in the absence of resuscitative equipment or in unmonitored settings and in patients with acute or severe bronchial asthma or hy

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - hydromorphone hydrochloride 32mg - modified release tablet - 32 mg - active: hydromorphone hydrochloride 32mg excipient: butylated hydroxytoluene cellulose acetate hypromellose iron oxide black iron oxide yellow macrogol 3350 magnesium stearate opacode black ns-78-17821 opadry clear ys-1-19025-a opadry white y-30-18037 polyethylene oxide povidone sodium chloride - jurnista is indicated in the treatment of moderate to severe chronic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - hydromorphone hydrochloride, quantity: 50 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; citric acid - dilaudid-hp injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - hydromorphone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; citric acid - dilaudid-hp injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.